Analysts’ Updated EPS Estimates for January, 14th (ALO, AMADY, AMTB, ATEC, AVEO, AXSM, BILI, BN, CDXS, CON)

Analysts’ updated eps estimates for Monday, January 14th:

Alstom (EPA:ALO) had its buy rating reissued by analysts at UBS Group AG.

Berenberg Bank initiated coverage on shares of AMADEUS IT HLDG/ADR (OTCMKTS:AMADY). The firm issued a buy rating on the stock.

Stephens started coverage on shares of Mercantil Bank (NASDAQ:AMTB). Stephens issued an equal weight rating on the stock.

Alphatec (NASDAQ:ATEC) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $4.00 target price on the stock. The analysts wrote, “We are maintaining our Buy rating of ATEC and our 12-month price target of $4.00 per diluted share. We derive our price target based on: 1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2025 sales of $244M; and 2) a discounted cash flow analysis using the projected free cash flow to the firm through 2025 and assuming a 10% discount rate and 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $3.87 per share, which we round to $4.00.””

AVEO Pharmaceuticals (NASDAQ:AVEO) had its buy rating reissued by analysts at HC Wainwright. They currently have a $9.00 target price on the stock. The analysts wrote, “We maintain our Buy rating on AVEO and our 12-month price target of $9.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $1.5B for the products and add in cash and cash equivalents of $18M to arrive at a 12-month price target of $9.16 per diluted share, which we round to $9.00.””

Axsome Therapeutics (NASDAQ:AXSM) had its buy rating reissued by analysts at HC Wainwright. They currently have a $15.00 price target on the stock. The analysts wrote, “We utilize a risk-adjusted net present value (rNPV) approach to assessing Axsome shares. We apply a 20% discount rate to all future cash flows along with a 28.1% effective tax rate and 33% sales and marketing rate. The probabilities of approval for all of Axsome’s candidates currently range from 10% to 30%.””

Daiwa Capital Markets initiated coverage on shares of Bilibili (NASDAQ:BILI). The firm issued an outperform rating on the stock.

Danone (EPA:BN) was given a €72.00 ($83.72) target price by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

Codexis (NASDAQ:CDXS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $16.50 price target on the stock. The analysts wrote, “We maintain our Buy rating of CDXS and our 12-month price target of $16.50 per share. We derive our price target based on the average of three valuation methods: 1) price-sales multiple analysis applying a 3x multiple to our 2025 risk-adjusted revenue estimate discounted at 12%; 2) price-earnings multiple analysis applying a 23x multiple to our 2025 estimated earnings discounted at 12%; and 3) discounted free cash flow analysis assuming a 12% discount rate and a 2% terminal growth rate.””

Continental (ETR:CON) was given a €150.00 ($174.42) target price by analysts at JPMorgan Chase & Co.. The firm currently has a neutral rating on the stock.

Continental (ETR:CON) was given a €145.00 ($168.60) target price by analysts at Jefferies Financial Group Inc. The firm currently has a neutral rating on the stock.

Correvio Pharma (NASDAQ:CORV) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $10.50 price target on the stock. The analysts wrote, “We maintain our Buy rating of Correvio and our 12-month price target of $10.50 per share. We derive our price target based on the average of two valuation methods:1) price-sales multiple analysis applying a 4x multiple to our 2025 risk-adjusted revenue estimate discounted at 12%; and 2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. 1) commercial; 2) clinical; 3) partnership; 4) financial; and 5) intellectual property.””

Morgan Stanley initiated coverage on shares of Carvana (NYSE:CVNA). Morgan Stanley issued an underweight rating on the stock.

Needham & Company LLC started coverage on shares of Domo (NASDAQ:DOMO). The firm issued a buy rating on the stock.

Forty Seven (NASDAQ:FTSV) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $21.00 target price on the stock. The analysts wrote, “We maintain our Buy rating on FTSV and our 12-month price target of $21.00 per share. We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and 3% terminal growth rate. We derive rNPV of $975M for 5F9 and add in cash, cash equivalents, and short-term investments of $154M to arrive at a 12-month price target of $20.79 per diluted share, which we round to $21.00.””

Henkel AG & Co KGaA (FRA:HEN3) was given a €93.00 ($108.14) target price by analysts at UBS Group AG. The firm currently has a sell rating on the stock.

Daiwa Capital Markets initiated coverage on shares of HUYA (NYSE:HUYA). Daiwa Capital Markets issued a neutral rating on the stock.

BTIG Research started coverage on shares of Innovative Industrial Properties (NYSE:IIPR). They issued a buy rating on the stock.

Immune Design (NASDAQ:IMDZ) had its buy rating reissued by analysts at HC Wainwright. The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential contribution from pipeline development. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.””

Kion Group (FRA:KGX) had its buy rating reiterated by analysts at UBS Group AG.

Kindred Biosciences (NASDAQ:KIN) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $19.00 price target on the stock. The analysts wrote, “We maintain our Buy rating of KIN and our 12-month price target of $19.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate. We derive an rNPV of $605M for the pipeline products and add in $92M in cash and cash equivalents to arrive at a 12-month price target of $18.53 per diluted share, which we round to $19.00.””

KeyCorp assumed coverage on shares of Linde (NYSE:LIN). KeyCorp issued an overweight rating on the stock.

Marvell Technology Group (NASDAQ:MRVL) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $25.00 target price on the stock. The analysts wrote, “In conjunction with our industry report published this morning entitled, CES C1H19″, we are reducing forward revenue and NG EPS estimates for the majority of our semiconductor companies under coverage including Marvell. Highlights from our CES meeting appears below.””

Nestlé (VTX:NESN) was given a CHF 90 price target by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

Netflix (NASDAQ:NFLX) had its sell rating reiterated by analysts at Wedbush. The firm currently has a $150.00 price target on the stock.

Rheinmetall (ETR:RHM) had its buy rating reiterated by analysts at UBS Group AG.

Berenberg Bank started coverage on shares of Sabre (NASDAQ:SABR). They issued a sell rating on the stock.

Siemens (FRA:SIE) had its buy rating reissued by analysts at UBS Group AG.

Tecogen (NASDAQ:TGEN) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock. The analysts wrote, “Our $6.00 price target for the company is derived using a DCF analysis. For our analysis, we have projected total revenues to increase from an estimated $38.1M in 2018 to $130.2M in 2025, growing at a seven-year CAGR of 19.2%.””

Unilever (AMS:UNIA) was given a €49.00 ($56.98) price target by analysts at UBS Group AG. The firm currently has a neutral rating on the stock.

Volvo (STO:VOLV-B) had its sell rating reissued by analysts at UBS Group AG.

Receive News & Ratings for Alstom SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alstom SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply